A Healthy Volunteer Study With Inhaled GSK573719 and Placebo
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A Single Centre, Randomized, Double-blind, Dose Ascending, Placebo-controlled Study, in Two Parts, to Evaluate the Safety, Tolerability and Pharmacokinetics of Escalating Single and Repeat Inhaled Doses of GSK573719 and Placebo Formulated With the Excipient Magnesium Stearate, in Healthy Subjects and in a Healthy Population of Cytochrome P450 Isoenzyme 2D6 Poor Metabolisers.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female 18 to 65 years of age inclusive.
Non-childbearing women or women of child bearing potential who agree to use contraception
Subject has had their CYP2D6 genotype confirmed and can be included in either of the following parts:
Part 1: may include extensive, intermediate and ultra-rapid metabolizers
Part 2: includes only poor (no enzyme activity) metabolizers, with previously confirmed phenotype
Body Mass Index within the range 18 - 30 kg/m2 (inclusive).
Capable of giving written informed consent
Normal lung function.
Non-smokers (never smoked or not smoking for >6 months with <10 pack years history (Pack years = (cigarettes per day smoked/20) x number of years smoked))
A signed and dated written informed consent is obtained from the subject
The subject is capable of giving informed consent
Available to complete the study
Any clinically important abnormality identified at the screening medical assessment (physical examination/medical history), clinical laboratory tests, or ECG (12-lead). 24hr Holter monitoring outside normal limits.
A history of breathing problems (i.e. history of asthmatic symptomatology).
Abnormal blood pressure.
Abnormal heart rate
The subject has a positive pre-study drug/alcohol screen.
A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within three months of screening.
A positive test for HIV antibody (if determined by the local SOPs).
History of high alcohol consumption within three months of the study
The subject has participated in a clinical trial and has received an IP within the following time period prior to the first dosing day in the current study: 30 days, five half-lives or twice the duration of the biological effect of the IP (whichever is longer).
Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
Use of prescription or non-prescription drugs, (except for simple analgesics e.g. paracetamol), including vitamins, herbal and dietary supplements (including St John's Wort) within seven days (or 14 days if the drug is a potential enzyme inducer) or five half-lives (whichever is longer) prior to the first dose of study medication
History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
Where participation in the study would result in donation of blood or blood products in excess of 500mL within a 56 day period.
Unwillingness or inability to follow the procedures outlined in the protocol.
Urinary cotinine levels indicative of smoking or history of regular use of tobacco- or nicotine-containing products prior to screening.
The subject is unable to use the novel dry powder inhaler correctly.
The subject has a known allergy or hypersensitivity to milk protein or the excipients magnesium stearate and lactose monohydrate.